Related Experiment Video
Updated: Feb 4, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Toward Precision Medicine in the Cardiorenal Syndrome
Nicholas Wettersten1, Alan S Maisel1, Dinna N Cruz1
1Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla, CA; and Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, California.
Abstract:
Although the field of oncology has made significant steps toward individualized precision medicine, cardiology and nephrology still often use a "one size fits all" approach. This applies to the intersection of the heart-kidney interaction and the cardiorenal syndrome as well. Recent studies have shown that the prognostic implications of worsening renal function (WRF) in acute heart failure are variable; thus, there is a need to differentiate the implications of WRF to better guide precise care. This may best be performed with biomarkers that can give the clinician a real-time evaluation of the physiologic state at the time of developing WRF. This review will summarize current cardiac and renal biomarkers and their status in the evaluation of cardiorenal syndrome. Although we have made progress in our understanding of this syndrome, further investigation is needed to bring precision medicine into routine clinical practice for the care of patients with cardiorenal syndrome.
Insights
Precision medicine is lacking in cardiorenal syndrome care. Biomarkers are needed to personalize treatment for worsening renal function (WRF) in acute heart failure, improving patient outcomes.
Area of Science:
- Cardiology and Nephrology
- Cardiorenal Syndrome
- Precision Medicine
Background:
- Cardiology and nephrology lag behind oncology in adopting precision medicine.
- A "one size fits all" approach is common in managing cardiorenal syndrome.
- The prognostic impact of worsening renal function (WRF) in acute heart failure is highly variable.
Purpose of the Study:
- To review current cardiac and renal biomarkers for cardiorenal syndrome evaluation.
- To highlight the need for biomarkers to guide precise care for WRF in acute heart failure.
- To assess the current status of biomarkers in clinical practice for cardiorenal syndrome.
Main Methods:
- Literature review of current cardiac and renal biomarkers.
- Analysis of biomarker utility in assessing cardiorenal syndrome.
- Evaluation of the potential for biomarkers in precision medicine for cardiorenal syndrome.
Main Results:
- Current biomarkers offer insights but are insufficient for routine precision care in cardiorenal syndrome.
- Significant variability exists in the prognostic implications of WRF.
- Real-time physiological evaluation via biomarkers is crucial for personalized WRF management.
Conclusions:
- Further research is essential to integrate precision medicine into cardiorenal syndrome management.
- Biomarker development is key to differentiating WRF implications and tailoring treatments.
- Bridging the gap between research and clinical practice is needed for advanced cardiorenal care.
Related Concept Videos
Uncertainty in Measurement: Accuracy and Precision
Microorganisms in Medicine and Therapeutics
Accuracy and Precision
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Precise Definition of a Limit
Nephrotic Syndrome I : Introduction

